Approval is based on results from the Phase III VALIANT trial (NCT05067127), in which Empaveli demonstrated a 68% reduction ...

Aetna enhances user experience with AI-driven Care Paths, simplifying health navigation and personalizing care for members ...

The results showed that people started mirroring the eating habits of GLP-1 users even when they weren’t taking the ...

The transaction brings larsucosterol, an investigational treatment for alcoholic hepatitis, under Bausch Health’s portfolio ...